Anteris Technologies Global Corp. reported its financial results for the third quarter ended September 30, 2026, filing its Form 10-Q with the SEC and providing supplementary disclosures for the Australian Securities Exchange (ASX). The company highlighted its ongoing development of the DurAVR THV biomimetic heart valve and disclosed $576,000 in payments to related parties, including executive salaries and director fees.
Anteris Technologies Global Corp. reported a net loss of $78.5 million for the nine months ended September 30, 2026, driven by significant research and development expenses of $62.2 million. The company's financial position improved substantially during the period, with cash and cash equivalents increasing to $232.8 million following the issuance of common stock, resulting in a total stockholders' equity of $226.8 million.
Anteris Technologies Global Insider L1 Capital Pty Ltd Buys $1.96M of Stock
L1 Capital Pty Ltd bought 272,695 shares of Anteris Technologies Global Corp. at $7.18 a share, worth $1.96M in total on Oct 6, 2026. Shares held after the trade: 6,358,271 (+4.5%).
Anteris Technologies Global Insider L1 Capital Pty Ltd Buys $6.71M of Stock
L1 Capital Pty Ltd bought 884,809 shares of Anteris Technologies Global Corp. at $7.51 to $7.78 a share (average $7.58) in 2 transactions, worth $6.71M in total between Oct 2, 2026 and Oct 5, 2026. Shares held after the trade: 12,778,380 (+5.3%).
Anteris Technologies Global Insider L1 Capital Pty Ltd Buys $3.03M of Stock
L1 Capital Pty Ltd bought 397,226 shares of Anteris Technologies Global Corp. at $7.60 to $7.72 a share (average $7.62) in 2 transactions, worth $3.03M in total between Sep 30, 2026 and Oct 1, 2026. Shares held after the trade: 5,200,767 (+6.6%).
Anteris Technologies Global Corp. entered into an amendment to its existing Supply & Quality Agreement with Harvey Industries Group Pty Ltd. The amendment extends the contract term until December 31, 2026, or until a new replacement agreement is executed, ensuring continued operational supply for the company's subsidiary.
Anteris Technologies approved contingent equity grants for CEO Wayne Paterson (1,200,000 stock options and 800,000 PSUs) and David St Denis (414,000 stock options and 485,000 PSUs). The grants are subject to stockholder approval and feature a four-year vesting schedule tied to continuous employment and performance milestones.